25/11/2021at 15:29

Novo Nordisk is making progress toward stabilizing Wegovy supply

Danish pharmaceutical company Novo Nordisk is hard at work with stabilizing the supply of its obesity drug Wegovy, which has been in high demand in the US since its June launch.

By Marketwire og Ulrich Quistgaard, translated by Daniel Pedersen

Novo Nordisk is currently making progress in securing its supply of the obesity drug Wegovy, the company reports on its website.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

European interest in Wegovy expected to match US demand, says EVP at Novo Nordisk
For subscribers
Wegovy weight loss results "very encouraging," says Novo EVP
For subscribers
Year-to-date obesity drug sales at Novo Nordisk surpass all of 2020
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Per Wold-Olsen officially stepped down as GN's chair at the company's AGM | Foto: Mik Eskestad

Hearing health

Former GN chair says there have been no acquisition signs from Demant owner

Per Wold-Olsen left the chairperson position two weeks ago after 15 years – he now reveals there haven’t been acquisition talks behind closed doors during his time at the company.

For subscribers

Regulation

CHMP recommends nine drugs in March

For subscribers

Nicolai Buhl, executive vice president for innovation at Coloplast, is busy winning a clinical contest against a catheter competitor | Foto: Mik Eskestad

Medtech

Coloplast challenges its biggest catheter competitor in clinical contest

For subscribers

Other

Top news from MedWatch this week

Pharma & biotech

Former Bavarian Nordic chairman sees opportunities in Johnson & Johnson's RSV exit

For subscribers

Pharma & biotech

Novo Nordisk helps Canada resolve Ozempic issue

For subscribers

Novo Nordisk helps Canada resolve Ozempic issue

Americans were reportedly crossing the border seeking the diabetes drug with a strong weight-loss effect until barred from purchases.

For subscribers

Minister for the Interior and Health of Denmark Sophie Løhde must answer questions concerning Novo Nordisk's funding of a Danish patient group | Photo: Ida Marie Odgaard

Pharma & biotech

Danish health minister to answer questions about Novo Nordisk sponsorship of patient group

The Danish minister for health has six business days to answer questions posed by a parliamentarian.

For subscribers

Hearing health

Former GN chair says there have been no acquisition signs from Demant owner

Per Wold-Olsen left the chairperson position two weeks ago after 15 years – he now reveals there haven’t been acquisition talks behind closed doors during his time at the company.

For subscribers